Dipeptidyl peptidase-4 inhibitors may lower body temperature: A case-control study

Shuichi Okada; Kazuya Okada; Junichi Okada; Koji Kikkawa; Eijiro Yamada; Tsugumichi Saito; Tetsuro Andou; Kihachi Ohshima; Yawara Niijima

doi:10.1016/j.dsx.2024.103142

Dipeptidyl peptidase-4 inhibitors may lower body temperature: A case-control study

Diabetes Metab Syndr. 2024 Oct 31;18(10):103142. doi: 10.1016/j.dsx.2024.103142. Online ahead of print.

Authors

Shuichi Okada¹, Kazuya Okada², Junichi Okada³, Koji Kikkawa⁴, Eijiro Yamada⁵, Tsugumichi Saito⁵, Tetsuro Andou⁴, Kihachi Ohshima⁴, Yawara Niijima⁶

Affiliations

¹ Soleiyu Asahi Clinic, 1-35-9 Asahi-chou, Maebashi, Gunma, 371-0014, Japan; Hidaka Hospital, 886 Nakao-machi, Takasaki, Gunma, 370-0001, Japan. Electronic address: okadash1823@gmail.com.
² Department of Orthopedic Surgery, Gunma University, 3-39-15 Showa-machi, Maebashi, Gunma, 371-8511, Japan.
³ Department of Medicine, Division of Endocrinology, Albert Einstein College of Medicine, 1301 Morris Park Ave., Price 369, Bronx, NY, 10461, USA.
⁴ Hidaka Hospital, 886 Nakao-machi, Takasaki, Gunma, 370-0001, Japan.
⁵ Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Maebashi, Gunma, 371-8511, Japan.
⁶ Soleiyu Asahi Clinic, 1-35-9 Asahi-chou, Maebashi, Gunma, 371-0014, Japan.

PMID: 39515183
DOI: 10.1016/j.dsx.2024.103142

Abstract

Aims: Dipeptidyl peptidase-4 inhibitors (DPP4i) enhance GABAergic transmission via the glucagon-like peptide-1 (GLP-1)/GLP-1 receptor pathway. Oral γ-aminobutyric acid (GABA) administration reduces body temperature in humans; thus, DPP4i may reduce body temperature in humans. Therefore, this study aimed to determine the effects of DPP4i administration on the body temperature of patients with type 2 diabetes (T2D).

Methods: This study included 128 outpatients with T2D who visited the hospital monthly from May to July 2022. The DPP4i group included 64 patients treated with DPP4i while the non-DPP4i group included 64 patients not treated with DPP4i. Body temperature was measured at the axilla point upon entry to the hospital and was compared between the two groups.

Results: The means of age, body mass index, T2D duration, systolic blood pressure, diastolic blood pressure, serum creatinine level, casual triglyceride level, high-density lipoprotein cholesterol level, low-density lipoprotein cholesterol level, casual plasma glucose level, and glycated hemoglobin level were not significantly different between the two groups. The mean body temperatures (°C) were 36.1 ± 0.2 and 36.4 ± 0.17 in the DPP4i and non-DPP4i groups, respectively (p = 1.123 E-05).

Conclusions: DPP4i reduced the body temperature of patients with T2D.

Keywords: Body temperature; Dipeptidyl peptidase-4 inhibitor; Type 2 diabetes.